Health Care
Resonance Health Limited (RHT)
Resonance Health is a medical technology company specializing in the development and delivery of non-invasive medical imaging analysis services. Operating globally, the company's core products include FerriScan® for liver iron concentration measurement and HepaFat-Scan® for liver fat quantification, both utilising MRI data. RHT is increasingly focused on leveraging artificial intelligence (AI) to expand its suite of diagnostic tools for various diseases.
Market Cap
A$22M
Shares on Issue
N/A
Price Chart
AI Analysis
As a micro-cap with a market capitalisation of A$22M, Resonance Health is a speculative investment. The company generates revenue from its established, regulatory-approved products like FerriScan®, which has a solid foothold in the niche market for monitoring iron overload. However, the company is not yet consistently profitable and its performance is heavily dependent on managing cash burn, as detailed in its quarterly 4C reports, while investing in R&D and sales to grow its core business.
The primary growth outlook for RHT is centered on the successful development and commercialisation of its AI-driven diagnostic pipeline, including tools for liver fibrosis (LiverSmart®) and potentially neurodegenerative diseases. Key catalysts include securing further regulatory approvals (FDA, TGA, CE), publishing positive clinical validation data, and signing new commercial agreements with hospitals, imaging centers, and pharmaceutical companies for use in clinical trials. The company's strategic direction is to transition from a service-based model to a more scalable, AI-powered software-as-a-service (SaaS) provider in the medical diagnostics space.
Bull Case
- • Established revenue base from globally approved products (FerriScan®, HepaFat-Scan®) provides a foundation for growth and de-risks the company compared to pre-revenue biotech peers.
- • Significant upside potential from its pipeline of AI-driven diagnostic tools, which target large addressable markets like non-alcoholic fatty liver disease (NAFLD/NASH).
- • Increasing global prevalence of chronic liver diseases and a shift towards non-invasive diagnostics act as strong industry tailwinds for both core and pipeline products.
Bear Case
- • Significant financing risk associated with its micro-cap status; the company may need to raise capital in the future, potentially at a discount, leading to shareholder dilution.
- • Long sales cycles and challenges in achieving widespread clinician adoption for new diagnostic technologies can slow revenue growth and delay profitability.
- • Competition from larger medical imaging companies, alternative diagnostic methods (e.g., blood tests, elastography), and other AI startups in the radiology space.
Market Sentiment
Based on 11 social posts
Recent mentions
General information about a stock
Introduction to Resonance Health Limited
Introduction to Resonance Health Limited
Recent Announcements
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveRHT, a commitments test entity on ASX, reports positive cash flow from operations and capital expenditcur for the quarter in Appendix 4C of their financial statements.
FAQs
What does RHT do?
Resonance Health provides non-invasive analysis of medical images, primarily MRIs, to diagnose and monitor human diseases. Its main commercial products are FerriScan® and HepaFat-Scan®, used globally to measure liver iron and fat, and it is developing new AI-powered tools for other conditions.
Is RHT a good investment?
RHT is a high-risk, high-reward speculative investment. The opportunity lies in its validated technology and the potential of its AI pipeline to capture a share of large diagnostic markets. However, risks include its small size, cash burn, competition, and the inherent uncertainty of regulatory approval and commercial adoption for new medical technologies.
What drives RHT's share price?
Key drivers include regulatory news (e.g., FDA/TGA approvals), results from clinical studies, commercial milestones like signing new hospital or pharmaceutical contracts, and quarterly cash flow reports (Appendix 4C) which indicate its financial runway and sales traction.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.